2017
Turning the tide against tuberculosis
Padayatchi N, Naidu N, Friedland G, Naidoo K, Conradie F, Naidoo K, O’Donnell M. Turning the tide against tuberculosis. International Journal Of Infectious Diseases 2017, 56: 6-9. PMID: 28167256, DOI: 10.1016/j.ijid.2017.01.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsBiomedical ResearchFemaleHIV InfectionsHumansMaleResearch Support as TopicTuberculosis, PulmonaryWorld Health Organization
2015
Care of the patient with XDR-TB who has failed treatment
Jacobson KB, Tate M, Eksteen F, Moll A, Padayatchi N, Friedland G, Shenoi S. Care of the patient with XDR-TB who has failed treatment. The Lancet Respiratory Medicine 2015, 3: 269-270. PMID: 25890645, PMCID: PMC4498160, DOI: 10.1016/s2213-2600(15)00109-5.Peer-Reviewed Original Research
2013
Case 29-2013 — A 32-Year-Old HIV-Positive African Man with Dyspnea and Skin Lesions
Cabot R, Rosenberg E, Harris N, Shepard J, Cort A, Ebeling S, McDonald E, Friedland G, Naidoo P, Abdool-Gafoor B, Moosa M, Ramdial P, Gandhi R. Case 29-2013 — A 32-Year-Old HIV-Positive African Man with Dyspnea and Skin Lesions. New England Journal Of Medicine 2013, 369: 1152-1161. PMID: 24047065, DOI: 10.1056/nejmcpc1305985.Peer-Reviewed Original Research
2012
Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting
Gandhi N, Andrews J, Brust J, Montreuil R, Weissman D, Heo M, Moll A, Friedland G, Shah N. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 90-97. PMID: 22236852, PMCID: PMC3302205, DOI: 10.5588/ijtld.11.0153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountCoinfectionDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFemaleHIV InfectionsHumansMaleMarkov ChainsMonte Carlo MethodPrevalencePrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSouth AfricaSurvival AnalysisTime FactorsTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryConceptsHuman immunodeficiency virusXDR-TB patientsRisk factorsAntiretroviral therapyXDR-TBDrug-resistant (XDR) TBImmunosuppressed human immunodeficiency virusStrong independent risk factorHigh HIV prevalence settingsMDR-TB patientsTB treatment programsIndependent risk factorYear of diagnosisDrug-resistant tuberculosisHIV prevalence settingsCells/Principal risk factorsCase-control studyAmplification of resistanceHigh mortality rateART initiationHIV testingImmunodeficiency virusPrevalence settingsMortality rate
2008
Exogenous Reinfection as a Cause of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Rural South Africa
Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, Moll AP, Pillay M, Friedland G, Sturm AW, Collaboration O. Exogenous Reinfection as a Cause of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Rural South Africa. The Journal Of Infectious Diseases 2008, 198: 1582-1589. PMID: 18847372, DOI: 10.1086/592991.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisXDR tuberculosisExogenous reinfectionHuman immunodeficiency virus (HIV) infectionEffective infection control strategiesInitial isolatesCause of MDRTB treatment programsTransmission of MDRCulture-positive tuberculosisHIV infection statusImmunodeficiency virus infectionInfection control strategiesDevelopment of MDRResistant tuberculosisMultidrug-ResistantHigh prevalenceVirus infectionPatientsReinfectionRural South AfricaTreatment programTuberculosisInfection statusTugela Ferry
2006
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV
Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. Journal Of Antimicrobial Chemotherapy 2006, 58: 1299-1302. PMID: 17032686, DOI: 10.1093/jac/dkl399.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAntibiotics, AntitubercularAnti-HIV AgentsBenzoxazinesCD4 Lymphocyte CountChromatography, High Pressure LiquidCyclopropanesDidanosineDrug Therapy, CombinationFemaleHIV InfectionsHumansLamivudineLongitudinal StudiesMaleOxazinesRifampinTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsExcellent clinical outcomesEfavirenz concentrationsClinical outcomesAntiretroviral therapyEfavirenz levelsAfrican patientsNon-detectable viral loadSmear-positive pulmonary TBLong-term clinical outcomesAdministration of efavirenzCD4 cell increaseHIV clinical outcomesPlasma efavirenz concentrationsCells/mm3Half of patientsTB regimenPulmonary TBPharmacokinetic interactionsTB outcomesTherapy completionRifampicin administrationViral loadTherapeutic rangePatientsHIV
2004
Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8
Cassol E, Page T, Mosam A, Friedland G, Jack C, Lalloo U, Kopetka J, Patterson B, Esterhuizen T, Coovadia HM. Therapeutic Response of HIV-1 Subtype C in African Patients Coinfected with either Mycobacterium tuberculosis or Human Herpesvirus-8. The Journal Of Infectious Diseases 2004, 191: 324-332. PMID: 15633090, DOI: 10.1086/427337.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountDrug Therapy, CombinationFemaleHerpesvirus 8, HumanHIV InfectionsHIV-1HumansMaleMiddle AgedMycobacterium tuberculosisReverse Transcriptase InhibitorsRNA, ViralSarcoma, KaposiTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsKaposi's sarcomaHIV-1Opportunistic infectionsViral loadAfrican patientsUndetectable HIV-1 RNA levelsCell countHIV-1 RNA levelsPlasma HIV-1 levelsHuman immunodeficiency virus (HIV) infectionHIV-1 subtype CKaplan-Meier survival analysisMycobacterium tuberculosisHIV-1 levelsImmunodeficiency virus infectionProportion of patientsTarget cell availabilityHuman herpesvirus 8Immune activationTreatment regimensSubtype CTherapeutic responseTreatment outcomesVirus infectionHerpesvirus 8